MAPUTO, Mozambique — Partnership will be the key to UNITAID’s new $50 million, five-year investment in increasing antimalarial treatment for pregnant women in sub-Saharan Africa.
The Transforming Intermittent Preventive Treatment for Optimal Pregnancy — or Tiptop — program will introduce community-level distribution of quality-assured sulfadoxine-pyrimethamine (SP) to 400,000 pregnant women and their babies in Mozambique, the Democratic Republic of the Congo, Nigeria, and Madagascar, and inform change in policy recommendations from the World Health Organization.
Get development's most important headlines in your inbox every day.
Thanks for subscribing!
Should your team be reading this?
Contact us about a group subscription to Pro.About the author
Gloria PallaresGloriaspv
Gloria Pallares is a journalist reporting on sustainable development, global health and humanitarian aid from Africa and Europe. Her work has appeared in a range of publications including El Pais, Forbes, CIFOR’s Forest News and the leading media outlets in Spain via the multimedia newswire Europa Press.
